ストックスクリーナーアプリを入手
48.24
3.97%
1.84
アフターアワーズ：
48.08
-0.16
-0.33%
前日終値:
$46.40
開ける：
$46.63
24時間の取引高:
577.79K
Relative Volume:
0.82
時価総額：
$1.84B
収益：
$17.39M
当期純損益:
$-135.89M
株価収益率:
-14.27
EPS:
-3.38
ネットキャッシュフロー:
$-123.00M
1週間 パフォーマンス:
+7.61%
1か月 パフォーマンス:
+26.95%
6か月 パフォーマンス:
+34.82%
1年 パフォーマンス:
+174.72%
1日の値動き範囲:
$45.98
$48.50
1週間の範囲:
$44.00
$48.50
52週間の値動き範囲:
$15.60
$52.99
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
名前
Tarsus Pharmaceuticals Inc
セクター
電話
(949) 409-9820
住所
15440 LAGUNA CANYON ROAD, IRVINE
TARS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| TARS | 48.24 | 1.84B | 17.39M | -135.89M | -123.00M | -3.38 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-20 | 開始されました | Goldman | Neutral |
| 2023-07-18 | 開始されました | William Blair | Outperform |
| 2023-05-18 | 開始されました | Guggenheim | Buy |
| 2022-08-01 | 開始されました | Barclays | Overweight |
| 2021-12-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-23 | 開始されました | Oppenheimer | Outperform |
| 2020-11-10 | 開始されました | BofA Securities | Buy |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-11-10 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Tarsus Pharmaceuticals Inc (TARS) 最新ニュース
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Jennison Associates LLC Buys 698,712 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade - MSN
22,493 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by GSA Capital Partners LLP - MarketBeat
What is Lifesci Capital's Forecast for TARS FY2024 Earnings? - MarketBeat
Tarsus Pharmaceuticals Appoints Kate Goodrich, MD, to its Board of Directors - Vision Monday
US$65.33That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results - Simply Wall St
Tarsus Pharmaceuticals stock target upgraded, holds buy on strong sales - Investing.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.3%Here's What Happened - MarketBeat
Midday Stock Roundup: Viant Tech Up Since Q3 Earnings - Orange County Business Journal
Trend Tracker for (TARS) - Stock Traders Daily
Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
The Goldman Sachs Group Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call Transcript - Insider Monkey
Tarsus Pharmaceuticals stock target upgraded, holds buy on strong sales By Investing.com - Investing.com UK
Paradigm Biocapital Advisors LP Increases Stake in Tarsus Pharma - GuruFocus.com
Prudential Financial Inc's Strategic Acquisition in Tarsus Pharm - GuruFocus.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 1-Year High After Analyst Upgrade - Defense World
Tarsus Pharmaceuticals stock soars to 52-week high of $52 - Investing.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 52-Week High After Analyst Upgrade - MarketBeat
Tarsus Pharmaceuticals stock soars to 52-week high of $52 By Investing.com - Investing.com UK
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $65.00 Price Target at Oppenheimer - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... By GuruFocus - Investing.com Canada
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
Tarsus Pharmaceuticals Reports Strong Q3 2024 Performance - TipRanks
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings: EPS of $(0.6 - GuruFocus.com
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements - GlobeNewswire
Tarsus Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors - The Manila Times
Tarsus Pharma Strengthens Board with Humana CMO Dr. Kate Goodrich Appointment | TARS Stock News - StockTitan
Jennison Associates LLC Increases Stake in Tarsus Pharmaceuticals Inc - GuruFocus.com
Tarsus Pharmaceuticals Appoints Elizabeth Yeu, MD, as Chief Medical Officer - Vision Monday
Lisanti Capital Growth LLC Takes $1.31 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals seesaws amid report Alcon interest has cooled - MSN
Creative Planning Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on Wednesday - MarketBeat
Creative Planning Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41% - Simply Wall St
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 - GlobeNewswire
Tarsus Pharmaceuticals stock hits 52-week high at $48.65 - Investing.com
Tarsus Pharmaceuticals stock hits 52-week high at $48.65 By Investing.com - Investing.com UK
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer - GlobeNewswire
Tarsus Pharmaceuticals appoints new Chief Medical Officer - Investing.com India
Tarsus Pharmaceuticals appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Papulopustular Rosacea Market to Expand Significantly by 2034, States DelveInsight Report | Sol-Gel Technologies, Galderma, CollaGenex Pharma, Tarsus Pharma, Pfizer - Barchart
Papulopustular Rosacea Market to Expand Significantly by 2034, - openPR
Tarsus Pharma Names Leading Ophthalmologist Dr. Elizabeth Yeu as New Chief Medical Officer | TARS Stock News - StockTitan
Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money - Simply Wall St
Tarsus Pharmaceuticals Inc (TARS) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):